BACKGROUND: CKS1B is a member of the highly conserved cyclin kinase subunit 1 (CKS1) family that interacts with cyclin-dependent kinases and plays an important role in cell cycle progression. We and others have shown that CKS1B amplification located on chromosome 1q21 is an adverse prognostic factor in multiple myeloma, but its relationship with CKS1B nuclear protein expression, is unclear. The aim of this study was to correlate nuclear CKS1B protein immunoreactivity, 1q21 amplification status, p27(Kip1) expression and survival in patients with newly-diagnosed multiple myeloma. DESIGN AND METHODS: Nuclear expression of CKS1B and p27(Kip1) was evaluated by immunohistochemistry in decalcified, paraffin-embedded bone marrow biopsies from 94 patients with newly diagnosed multiple myeloma. Clonal plasma cells of the bone marrow aspirates from the same cohort were examined for CKS1B gene status by interphase cytoplasmic fluorescence in situ hybridization. RESULTS: Fluorescence in situ hybridization detected the 1q21 amplification in 36 (38%) of the 94 patients and immunohistochemistry showed CKS1B protein expression in 37 (39%). Thirty-two (86%) of the 36 amplified (1q21) cases expressed CKS1B and 31 (84%) of the 37 CKS1B immunore-active cases had amplified 1q21. 1q21 amplification and CKS1B protein expression were strongly correlated (P<0.0001). CKS1B protein expression was inversely correlated with p27(Kip1) immunostaining (P<0.0001) and was associated with a shorter overall survival (median 44.5 versus 89.3 months, P<0.0001). CONCLUSIONS: Immunohistochemistry for CKS1B is a simple, rapid method that appears to predict 1q21 amplification and adverse outcome for risk stratification of patients with multiple myeloma.
BACKGROUND:CKS1B is a member of the highly conserved cyclin kinase subunit 1 (CKS1) family that interacts with cyclin-dependent kinases and plays an important role in cell cycle progression. We and others have shown that CKS1B amplification located on chromosome 1q21 is an adverse prognostic factor in multiple myeloma, but its relationship with CKS1B nuclear protein expression, is unclear. The aim of this study was to correlate nuclear CKS1B protein immunoreactivity, 1q21 amplification status, p27(Kip1) expression and survival in patients with newly-diagnosed multiple myeloma. DESIGN AND METHODS: Nuclear expression of CKS1B and p27(Kip1) was evaluated by immunohistochemistry in decalcified, paraffin-embedded bone marrow biopsies from 94 patients with newly diagnosed multiple myeloma. Clonal plasma cells of the bone marrow aspirates from the same cohort were examined for CKS1B gene status by interphase cytoplasmic fluorescence in situ hybridization. RESULTS: Fluorescence in situ hybridization detected the 1q21 amplification in 36 (38%) of the 94 patients and immunohistochemistry showed CKS1B protein expression in 37 (39%). Thirty-two (86%) of the 36 amplified (1q21) cases expressed CKS1B and 31 (84%) of the 37 CKS1B immunore-active cases had amplified 1q21. 1q21 amplification and CKS1B protein expression were strongly correlated (P<0.0001). CKS1B protein expression was inversely correlated with p27(Kip1) immunostaining (P<0.0001) and was associated with a shorter overall survival (median 44.5 versus 89.3 months, P<0.0001). CONCLUSIONS: Immunohistochemistry for CKS1B is a simple, rapid method that appears to predict 1q21 amplification and adverse outcome for risk stratification of patients with multiple myeloma.
Authors: Norma C Gutiérrez; Juan L García; Jesús M Hernández; Eva Lumbreras; Mariana Castellanos; Ana Rasillo; Gema Mateo; José M Hernández; Sonia Pérez; Alberto Orfao; Jesús F San Miguel Journal: Blood Date: 2004-07-06 Impact factor: 22.113
Authors: Martin Filipits; Gudrun Pohl; Thomas Stranzl; Hannes Kaufmann; Jutta Ackermann; Heinz Gisslinger; Hildegard Greinix; Andreas Chott; Johannes Drach Journal: Clin Cancer Res Date: 2003-02 Impact factor: 12.531
Authors: Fabian Bock; Gary Lu; Samer A Srour; Sameh Gaballa; Heather Y Lin; Veerabhadran Baladandayuthapani; Medhavi Honhar; Maximilian Stich; Nina Das Shah; Qaiser Bashir; Krina Patel; Uday Popat; Chitra Hosing; Martin Korbling; Ruby Delgado; Gabriela Rondon; Jatin J Shah; Sheeba K Thomas; Elisabet E Manasanch; Berend Isermann; Robert Z Orlowski; Richard E Champlin; Muzaffar H Qazilbash Journal: Biol Blood Marrow Transplant Date: 2016-09-13 Impact factor: 5.742
Authors: C Gu; Y Yang; R Sompallae; H Xu; V S Tompkins; C Holman; D Hose; H Goldschmidt; G Tricot; F Zhan; S Janz Journal: Leukemia Date: 2015-12-09 Impact factor: 11.528
Authors: Susanne Kratzat; Viktoriya Nikolova; Cornelius Miething; Alexander Hoellein; Stephanie Schoeffmann; Oliver Gorka; Elke Pietschmann; Anna-Lena Illert; Jürgen Ruland; Christian Peschel; Jonas Nilsson; Justus Duyster; Ulrich Keller Journal: PLoS One Date: 2012-05-18 Impact factor: 3.240
Authors: Anna A Brożyna; Andrew Aplin; Cynthia Cohen; Grant Carlson; Andrew Joseph Page; Michael Murphy; Andrzej T Slominski; J Andrew Carlson Journal: Oncotarget Date: 2017-12-23